FDA Peptide Reclassification 2026: What It Means for Patients — and Why Physician Oversight Matters More Than Ever
By the physicians of Amanecia Health | March 4, 2026 On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides previously placed on the FDA’s Category 2 restricted list will be moved back to Category 1 — restoring legal access through licensed compounding pharmacies with a physician’s […]